Kuala lumpur: AdipoLABs Co Ltd and Red and Blue Co Ltd from Korea, along with their Malaysian subsidiary AdipoLABs Healthcare (M) Sdn Bhd, have officially inaugurated the new AdipoLABs regional office for the Asia-Pacific region. This strategic expansion aims to enhance its leadership in non-invasive healthcare and foster a robust MedTech ecosystem in Malaysia and across ASEAN.
According to BERNAMA News Agency, AdipoLABs Co Ltd chief executive officer Han Sung-ho emphasized that the company's presence is expected to drive knowledge transfer, foster research and development collaboration, provide industry-standard training, and enhance preventive healthcare capabilities. Han highlighted the potential of uniting hyperthermia technology with local expertise to expedite the adoption of advanced solutions and improve patient outcomes globally. He described the collaboration as a blueprint for international healthcare partnerships.
To mark the opening, AdipoLABs signed two Memoranda of Understanding (MoUs) with the University of Cyberjaya (UoC), formalizing a partnership to advance healthcare innovation, clinical research, and talent development. A significant aspect of the first MoU is a comprehensive internship program with UoC's physiotherapy programs under the Faculty of Health, offering six-month placements and potential job opportunities to provide students with real-world experience.
Students from the Faculty of Health will work with AdipoLABs' Pain Bot device, enhancing their skills in pain detection and treatment. Meanwhile, students from the School of Biomedical Engineering will support AdipoLABs' technical operations, focusing on after-sales service and device maintenance. As part of the partnership, AdipoLABs will implement a strategic client engagement initiative, allowing interns to demonstrate device effectiveness and provide on-site support at client facilities.
AdipoLABs Healthcare (M) Sdn Bhd director Dr Isaac R. Joseph stated that the initiative reflects the company's commitment to nurturing talent, creating pathways to permanent employment, and ensuring the optimal use of its technology. The collaboration also extends to clinical research, with UoC professors and students conducting studies on various AdipoLABs medical devices to generate evidence-based insights for publication in reputable journals.
Dr Joseph expressed enthusiasm about the collaboration with UoC, noting its potential to cultivate local talent and drive Malaysian healthcare innovation. The partnership offers UoC students valuable hands-on experience with technologies like Pain Bot and expands clinical research to enhance pain management solutions for patients across Malaysia and ASEAN.
In a parallel effort to advance physiotherapy education, AdipoLABs Malaysia, Red and Blue Co Ltd, and UoC signed a second MoU focusing on knowledge transfer and medical device donation. Under this agreement, AdipoLABs Malaysia will donate a Pain Bot unit to UoC, enabling students to access cutting-edge pain detection and treatment technology and strengthening their knowledge in musculoskeletal pain management.
AdipoLABs, registered under the Ministry of Health (MOH) as a medical device establishment with the Medical Device Authority (MDA), anchors this collaboration with proven regulatory credibility and a strong commitment to quality and innovation.
UoC vice-chancellor Dr David Whitford noted that their certified standing reinforces UoC's ambition to accelerate evidence-based research and industry-ready healthcare solutions. He emphasized that AdipoLABs' partnership with UoC is not just a collaboration but a direct investment in the next generation of healthcare professionals.
Further strengthening the collaboration, Prof Dr Yoo Seung-mo from South Korea, the inventor of the Pain Bot, will serve as an adjunct professor at UoC. He will provide on-site training and ongoing remote mentorship, ensuring students receive expert guidance in utilizing the Pain Bot technology and applying advanced pain detection and treatment techniques.
Together, UoC and AdipoLABs are positioned to drive forward Malaysia's healthcare innovation agenda with greater confidence and impact.